Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $16.22

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have been assigned an average rating of "Moderate Buy" from the ten brokerages that are presently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $16.22.

FOLD has been the topic of a number of research reports. Wall Street Zen cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. UBS Group raised their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Wells Fargo & Company lowered their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. Needham & Company LLC reissued a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Finally, The Goldman Sachs Group reduced their price target on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd.

Amicus Therapeutics Price Performance

Shares of Amicus Therapeutics stock traded down $0.25 during midday trading on Friday, hitting $5.80. 6,166,502 shares of the company traded hands, compared to its average volume of 3,014,593. The firm's fifty day moving average price is $6.44 and its 200-day moving average price is $8.26. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of -64.44 and a beta of 0.54. Amicus Therapeutics has a 12 month low of $5.78 and a 12 month high of $12.65. The company has a debt-to-equity ratio of 2.02, a quick ratio of 2.47 and a current ratio of 3.34.

Institutional Trading of Amicus Therapeutics

Several institutional investors have recently added to or reduced their stakes in FOLD. Wellington Management Group LLP lifted its position in shares of Amicus Therapeutics by 18.8% in the 4th quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company's stock worth $268,112,000 after purchasing an additional 4,497,950 shares during the period. Nuveen LLC acquired a new stake in shares of Amicus Therapeutics during the first quarter worth $28,741,000. Vestal Point Capital LP bought a new position in Amicus Therapeutics during the fourth quarter worth $31,557,000. Norges Bank acquired a new position in Amicus Therapeutics in the fourth quarter valued at $29,033,000. Finally, Millennium Management LLC boosted its position in Amicus Therapeutics by 635.1% during the first quarter. Millennium Management LLC now owns 3,359,389 shares of the biopharmaceutical company's stock valued at $27,413,000 after acquiring an additional 2,902,375 shares during the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.